OS Therapies: Last patient in OST-HER2 Osteosarcoma trial gest last dose

OS Therapies announced that the last patient enrolled in the AOST-2121 clinical tria of OST-HER2 in recurred, resected Osteosarcoma OS – has received its last treatment dose. This last patient is expected to complete its final radiological imaging evaluation as part of the 12-month Event Free Survival primary endpoint analysis by early in the fourth quarter of 2024. Concurrently, the Company will close all clinical trial sites and lock the database in preparation for data analysis and topline data readout that is expected to be announced in the fourth quarter of 2024. OST-HER2, a biologic therapeutic candidate, is a Lm or Listeria monocytogenes,vector-based off-the-shelf immunotherapeutic vaccine designed to prevent metastasis, delay recurrence, and increase overall survival in patients with Osteosarcoma. …AOST-2121 has achieved full enrollment of 41 patients treated with OST-HER2 at 21 clinical trial sites across the United States. The primary endpoints for the AOST-2121 study are Event Free Survival at 12 months and Overall Survival at 36 months, with interim … The addition of the data from this final patient, along with Patient #40, will enhance interim data announced in conjunction with ASCO 2024. This is in addition to previously reported Phase I clinical data in Breast cancer, which the Company plans to target after Osteosarcoma. We thank the patients, families, clinicians, researchers, assistants and the entire Osteosarcoma community for supporting this important and ground-breaking trial.